Global Hyperuricemia Drugs Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Hyperuricemia Drugs Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Hyperuricemia is the type of condition wherein an excessive level of uric acid is produced in the blood. The level of uric acid in the blood is the balance between the breakdown of purines and the rate of uric acid excretion. The alteration in the uric acid level may cause hyperuricemia. High uric acid can result in serious diseases such as painful arthritis called gout.
Hyperuricemia Drugs report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Hyperuricemia Drugs market is projected to reach US$ 4556.4 million in 2029, increasing from US$ 2140 million in 2022, with the CAGR of 11.4% during the period of 2024 to 2029. Demand from Gout and Renal Calculus are the major drivers for the industry.
Globally, the number of patients with hyperuricemia and gout is increasing year by year. According to statistics, the number of patients with hyperuricemia and gout in the world will reach 930 million in 2020, and the number of patients with hyperuricemia and gout in the world will be in 1.03 billion people in 2022.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Hyperuricemia Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Horizon Therapeutics plc
Takeda Pharmaceutical Company Ltd
Mylan NV
Novartis International AG
Regeneron Pharmaceuticals
Romeg Therapeutics
Teijin Pharma Ltd
Lannett Company, Inc
GSK Plc
Segment by Type
NSAIDs
Xanthine Oxidase Inhibitor
Selective Uric Acid Reabsorption Inhibitor
Carbonic Anhydrase Inhibitor
Glucocorticoid
Other
Gout
Renal Calculus
Other
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Hyperuricemia Drugs market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Hyperuricemia Drugs, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Hyperuricemia Drugs industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Hyperuricemia Drugs in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Hyperuricemia Drugs introduction, etc. Hyperuricemia Drugs Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Hyperuricemia Drugs market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Hyperuricemia Drugs report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Hyperuricemia Drugs market is projected to reach US$ 4556.4 million in 2029, increasing from US$ 2140 million in 2022, with the CAGR of 11.4% during the period of 2024 to 2029. Demand from Gout and Renal Calculus are the major drivers for the industry.
Globally, the number of patients with hyperuricemia and gout is increasing year by year. According to statistics, the number of patients with hyperuricemia and gout in the world will reach 930 million in 2020, and the number of patients with hyperuricemia and gout in the world will be in 1.03 billion people in 2022.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Hyperuricemia Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Horizon Therapeutics plc
Takeda Pharmaceutical Company Ltd
Mylan NV
Novartis International AG
Regeneron Pharmaceuticals
Romeg Therapeutics
Teijin Pharma Ltd
Lannett Company, Inc
GSK Plc
Segment by Type
NSAIDs
Xanthine Oxidase Inhibitor
Selective Uric Acid Reabsorption Inhibitor
Carbonic Anhydrase Inhibitor
Glucocorticoid
Other
Segment by Application
Gout
Renal Calculus
Other
Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Hyperuricemia Drugs market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Hyperuricemia Drugs, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Hyperuricemia Drugs industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Hyperuricemia Drugs in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Hyperuricemia Drugs introduction, etc. Hyperuricemia Drugs Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Hyperuricemia Drugs market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices